• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

For many suffering from depression, traditional therapy and medication are ineffective. Personalized treatment may be the solution.

Cue is an intervention platform for digital devices that translates passively acquired normal sensor data from smartphones into personalised micro-interventions that improve mental health. We analyzed the most effective-fit personal ML models for each subject using Shapley values to identify their feature predictors and reveal distinct features that are able to change mood as time passes.

Predictors of Mood

postpartum depression treatment near me is one of the leading causes of mental illness.1 Yet, only half of those suffering from the condition receive treatment1. To improve outcomes, healthcare professionals must be able to recognize and treat patients who are the most likely to benefit from certain treatments.

Personalized depression treatment is one way to do this. By using mobile phone sensors and an artificial intelligence voice assistant, and other digital tools, researchers at the University of Illinois Chicago (UIC) are working on new ways to determine which patients will benefit from which treatments. Two grants worth more than $10 million will be used to determine biological and behavior indicators of response.

The majority of research on predictors for depression treatment effectiveness has centered on sociodemographic and clinical characteristics. These include demographic factors such as age, sex and educational level, clinical characteristics like the severity of symptoms and comorbidities and biological indicators such as neuroimaging and genetic variation.

Very few studies have used longitudinal data in order to predict mood in individuals. They have not taken into account the fact that moods vary significantly between individuals. Therefore, it is critical to develop methods that allow for the identification of different mood predictors for each person and treatments effects.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. The team is able to develop algorithms to recognize patterns of behaviour and emotions that are unique to each individual.

The team also devised an algorithm for machine learning to identify dynamic predictors of the mood of each person's depression. The algorithm integrates the individual differences to create a unique "digital genotype" for each participant.

This digital phenotype was found to be associated with CAT-DI scores, which is a psychometrically validated symptom severity scale. However the correlation was not strong (Pearson's r = 0.08, BH-adjusted P-value of 3.55 x 10-03) and varied widely among individuals.

Predictors of symptoms

Depression is among the world's leading causes of disability1 yet it is often underdiagnosed and undertreated2. Depressive disorders are often not treated due to the stigma attached to them and the absence of effective treatments.

To aid in the development of a personalized treatment, it is essential to identify the factors that predict symptoms. The current methods for predicting symptoms rely heavily on clinical interviews, which are unreliable and only identify a handful of symptoms associated with depression.

Machine learning is used to integrate continuous digital behavioral phenotypes captured through smartphone sensors and an online mental health tracker (the Computerized Adaptive Testing Depression Inventory CAT-DI) with other predictors of severity of symptoms could increase the accuracy of diagnostics and treatment efficacy for depression. These digital phenotypes allow continuous, high-resolution measurements and capture a variety of distinctive behaviors and activity patterns that are difficult to record using interviews.

The study comprised University of California Los Angeles students with mild depression treatment to severe depression symptoms who were enrolled in the Screening and Treatment for Anxiety and Depression program29, which was developed as part of the UCLA Depression Grand Challenge. Participants were referred to online assistance or medical care according to the severity of their depression. Those with a CAT-DI score of 35 65 were assigned online support with a peer coach, while those who scored 75 patients were referred for psychotherapy in person.

At baseline, participants provided a series of questions about their personal characteristics and psychosocial traits. The questions included age, sex and education and marital status, financial status and whether they were divorced or not, current suicidal ideas, intent or attempts, and the frequency with which they consumed alcohol. Participants also scored their level of depression symptom severity on a scale ranging from 0-100 using the CAT-DI. The CAT-DI tests were conducted every other week for participants that received online support, and once a week for those receiving in-person care.

Predictors of Treatment Response

Research is focusing on personalized treatment for depression. Many studies are focused on finding predictors that can aid clinicians in identifying the most effective drugs to treat each individual. Particularly, pharmacogenetics is able to identify genetic variants that determine how the body's metabolism reacts medicine to treat anxiety and depression antidepressants. This enables doctors to choose medications that are likely to be most effective for each patient, while minimizing the time and effort involved in trials and errors, while avoiding side effects that might otherwise hinder advancement.

Another promising method is to construct models for prediction using multiple data sources, such as data from clinical studies and neural imaging data. These models can be used to determine which variables are the most likely to predict a specific outcome, like whether a medication can improve symptoms or mood. These models can be used to predict the response of a patient to a treatment, which will help doctors to maximize the effectiveness of their treatment.

A new generation employs machine learning techniques such as algorithms for classification and supervised learning such as regularized logistic regression, and tree-based methods to integrate the effects of multiple variables and increase the accuracy of predictions. These models have been shown to be useful in predicting treatment outcomes like the response to antidepressants. These methods are becoming popular in psychiatry, and it is expected that they will become the standard for future clinical practice.

Research into the underlying causes of depression continues, as do ML-based predictive models. Recent findings suggest that depression is linked to dysfunctions in specific neural networks. This theory suggests that individualized depression treatment will be focused on treatments that target these neural circuits to restore normal function.

Internet-based-based therapies can be an option to accomplish this. They can provide a more tailored and individualized experience for patients. One study found that a web-based program was more effective than standard treatment in alleviating symptoms and ensuring the best quality of life for those suffering from MDD. Furthermore, a randomized controlled trial of a personalized treatment for depression demonstrated steady improvement and decreased adverse effects in a significant proportion of participants.

Predictors of Side Effects

A major obstacle in individualized depression treatment involves identifying and predicting which antidepressant medications will have very little or no side effects. Many patients take a trial-and-error approach, using a variety of medications being prescribed before settling on one that is effective and tolerable. Pharmacogenetics is an exciting new method for an efficient and specific approach to choosing antidepressant medications.

There are a variety of predictors that can be used to determine which antidepressant should be prescribed, including gene variations, phenotypes of the patient such as gender or ethnicity, and the presence of comorbidities. However it is difficult to determine the most reliable and valid predictors for a particular treatment is likely medicine to treat anxiety and depression require controlled, randomized trials with considerably larger samples than those normally enrolled in clinical trials. This is due to the fact that the identification of moderators or interaction effects may be much more difficult in trials that only take into account a single episode of treatment per participant, rather than multiple episodes of treatment over a period of time.

Additionally, the prediction of a patient's response to a specific medication will also likely require information on comorbidities and symptom profiles, and the patient's prior subjective experience of its tolerability and effectiveness. Currently, only some easily measurable sociodemographic and clinical variables are believed to be reliably associated with response to MDD factors, including gender, age race/ethnicity, SES BMI and the presence of alexithymia and the severity of depression symptoms.

Many issues remain to be resolved in the use of pharmacogenetics to treat depression. First, it is important to have a clear understanding and definition of the genetic mechanisms that cause depression, and a clear definition of an accurate indicator of the response to treatment. Ethics such as privacy and the responsible use genetic information are also important to consider. In the long-term, pharmacogenetics may offer a chance to lessen the stigma that surrounds mental health care and improve the treatment outcomes for patients with depression. However, as with any other psychiatric treatment, careful consideration and application is necessary. At present, the most effective option is to provide patients with a variety of effective depression medications and encourage them to speak openly with their doctors about their concerns and experiences.